Urolithiasis associated with atazanavir may mask a metabolic 'channelling' bias.
Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.
Giovanni
G
Guaraldi
Giovanni
G
Dolci
Antonio
A
Bellasi
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000069446:Atazanavir Sulfate; D003937:Diagnosis, Differential; D006801:Humans; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects*; D051436:Renal Insufficiency, Chronic / Q000175:diagnosis / Q000473:pathology; D052878:Urolithiasis / Q000139:chemically induced* / Q000175:diagnosis*
D019380:Anti-HIV Agents; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate
chronic kidney disease; metabolic syndrome; protease inhibitors